H.C. Wainwright analyst Douglas Tsao says that while a takeover of Sage Therapeutics (SAGE) comes as no surprise, but a deal with Supernus (SUPN) is unexpected, and “leaves open the door for ...

Another patient has died from acute liver failure after receiving Sarepta’s gene therapy for DMD ; After a quiet start to the ...

The BIO convention may be hosted by Boston this year, but that hasn’t stopped other states from getting in on the action.

SUPN inks deal to acquire Sage Therapeutics for up to $795 million, securing rights to depression drug Zurzuvae.